

AD_____

Award Number: W81XWH-12-1-0318

TITLE: Compound 49b Reduces Inflammatory Markers and Apoptosis after Ocular Blast Injury

PRINCIPAL INVESTIGATOR: Jena J. Steinle

CONTRACTING ORGANIZATION: University of Tennessee Health Science Center
Memphis, TN 38163

REPORT DATE: September 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE September 2013		2. REPORT TYPE Annual		3. DATES COVERED 15 August 2012 – 14 August 2013	
4. TITLE AND SUBTITLE Compound 49b Reduces Inflammatory Markers and Apoptosis after Ocular Blast Injury				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0318	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jena J. Steinle E-Mail: jsteinl1@uthsc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Tennessee Health Science Center Memphis, TN 38163				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT In year 1 of this project, we determined whether Compound 49b, a novel beta-adrenergic receptor agonist, could prevent increased inflammatory and apoptosis proteins in mice after exposure to ocular blast. Eyes from C57/BL6 mice were exposed to a blast of air from a paintball gun at 26psi. Eyes were collected at 4, 24, and 72 hours after blast exposure. In a subset of mice, Compound 49b eye drops (1mM dose) were applied within 4 hours, 24 hours, or 72 hours after blast. Three days after exposure to blast, all mice were sacrificed. One eye was used for protein analyses of TNF α , IL-1 α , Bax, Bcl-xL, caspase 3, and cytochrome C. The other eye was used for TUNEL labeling of apoptotic cells, which were co-labeled with NeuN to stain for retinal ganglion cells. We found that ocular exposure to 26psi of air pressure led to a significant increase in both inflammatory and apoptotic proteins. When Compound 49b was applied within 4 or 24 hours after blast, it mitigated the increase in inflammatory and apoptotic proteins. Ocular blast produces a significant increase in inflammatory and apoptotic proteins in the retina, specifically in retinal ganglion cells. These proteins are reduced after treatment with a topical beta-adrenergic receptor agonist. This data suggests local application of beta-adrenergic receptor agonists may be protective in ocular blast.					
15. SUBJECT TERMS inflammation, apoptosis, ocular blast, Compound 49b					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 19	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	1-3
Key Research Accomplishments.....	3
Reportable Outcomes.....	3
Conclusion.....	3
References.....	3
Appendices.....	4-13

Introduction

Ocular trauma constitutes one of the most common causes of unilateral morbidity and blindness in the world today^[1]. Due to improvements in body protective gear, the rates of combat-based morbidity and mortality have decreased; however, the number of ocular injuries has increased (from 0.57% during the Civil War to 13% in Desert Storm^[1, 2]. Ocular damage occurring in more recent wars is often caused by explosions with fragmentary munitions and represents the 4th most common injury in Operation Iraqi Freedom^[2]. Despite improvements in eye protective wear, soldiers report injuries even while wearing eye protection in 24% of cases; in most instances use of eyewear is undocumented^[2]. Thus, despite advances in military protective wear, the blast produced by many improvised explosive device (IEDs) pose a significant threat of closed and open globe injuries through the fragmentary munitions. With a goal of improving treatment for these types of injuries, we propose studies using a rodent eye-blast model designed to 1) identify the molecular/cellular pathways within ocular tissue that are activated in response to injury and 2) test the efficacy of a new drug which holds promise as a mitigator of these damage-triggered responses.

Damage to neuronal tissues of the brain and eye has been addressed in several previous studies. Results using various blast models, primarily to whole body, have demonstrated significant neuronal and glial damage, with increased levels of inflammatory markers in the brain after blast exposure^[3]. Other work has demonstrated that blast exposure damages the visual system tracts in the brain, producing scotomas and general blindness, Retinal hemorrhages were also reported but there was no in-depth retinal analysis. In a model of head blast injury, axonal injuries to the cerebellum, corticospinal system, and optic tract were noted^[4]. Using a similar model, another group found a significant increase in inflammation in the brain following blast exposure^[5]. Taken together, these findings suggest that blast injuries may trigger 1) inflammation by activation of specific inflammatory pathways, and 2) cell death by activation of apoptotic or other cell death pathways.

To better characterize direct retinal responses to injury in the absence of indirect effects from distant sites, our collaborator, Dr. Tonia Rex developed an eye-specific blast model. In preliminary studies, Dr. Rex found that her model generates an open waveform primary blast with a pressure level that can be carefully controlled by altering input pressures or distance from the eye. Use of this model produced some of the changes noted in IED blast warriors^[6]. We will use the eye-specific blast model to test two hypotheses: 1) We will test the hypothesis that principle retinal changes produced in this model include an activation of inflammatory pathways (associated with increased levels of inflammatory markers, specifically TNF α and IL-1 β) and apoptotic pathways (linked to increased apoptotic markers, specifically Bax, Bcl-xL, cytochrome C, Fas, and Fas ligand). 2) We will test the hypothesis that treatment with a novel anti-apoptotic and anti-inflammatory agent, Compound 49b^[7], within 1 day of blast injury will protect against retinal damage. We will further determine if the protective actions of Compound 49b involve insulin-like growth factor binding protein-3 (IGFBP-3) pathways, as we have shown this to be the case in its protection against apoptosis in an in vitro damage model using human retinal endothelial cells.

Body

Statement of Work-Aim 1. Using the eye blast model, establish the major effects of various blast intensities on retinal structure and function at three time points: immediately after injury (4 hours), shortly after injury (24 hours), or days after injury (3 days), In particular, we will focus on blast-induced changes in markers of apoptosis (Bax, Bcl-xL, cytochrome C, Fas, and Fas ligand) and inflammatory mediators (TNF α , IL-1 β). Our goal is to establish biomarkers that are predictive of the severity and extent of retinal damage and thus will be useful in assessing the efficacy of our proposed protective treatment described in Aim 2. Based on a significant amount of preliminary data, we foresee few problems in completing these experiments within year 1 of the award.

This aim has been completed and recently accepted in a manuscript to be published in the Journal of Neuroinflammation. Briefly, we found that a blast of 26Psi significantly increased inflammatory and apoptotic mediators in mice. This was mitigated if topical Compound 49b was added 4 hours or 24 hours after blast. Application of Compound 49b seventy-two hours after blast reduced levels of both inflammatory and apoptotic markers, but not to control levels.

Figure 1




Figure 1. ELISA results for TNF α (left) and IL-1 β (right) in mouse retina without exposure to blast (NT) or exposure to blast for 4, 24, or 72 hours or exposure to blast+Compound 49b for 4, 24, or 72 hours. *P<0.05 vs. NT. #P<0.05 vs. blast only at the same time point. N=5 mice for each group.

Figure 2




Figure 2. Western blot results for key pro-apoptotic proteins (Cytochrome C and Bax—top) and anti-apoptotic protein Bcl-xL (bottom left). ELISA results for cleaved caspase 3. * $P < 0.05$ vs. NT. # $P < 0.05$ vs. blast only at the same time point. $N = 5$ mice for each group.

Figure 3




Figure 3. TUNEL labeling and NeuN (retinal ganglion cell marker) in untreated mice (A), 4 hours post-blast (B), 4 hours post-blast+49b (C), 24 hours post-blast (D), 24 hours post-blast+49b (E), 72 hours post-blast (F) and 72 hours post-blast+49b (G). TUNEL labeling is green with NeuN staining is red. Scale bar is 50 μ m.

Statement of Work-Aim 2. Determine if topical treatment with Compound 49b provides protection against blast injury to retinal structure and function compared to baseline data obtained in Aim 1. We will further assess if our proposed biomarkers are predictive of the degree of protection provided. Finally, we will examine the role of IGFBP-3 (a downstream target of Compound 49b's actions) in providing retinal protection. The goal of these experiments is to establish the efficacy of our proposed treatment with Compound 49b and its likely mechanism of action and downstream targets, which in turn would provide additional treatment strategies or drug targets.

As shown above, Compound 49b is effective at mitigating the increased inflammatory and apoptotic protein levels observed after blast with 26Psi pressure. We are currently working on the actions of IGFBP-3 in regulation of response to blast injury. We have collected samples from the IGFBP-3 KO mice 72 hours after blast (10 mice). We have also collected retinal samples from 5 mice that were blasted and then treated with Compound 49b 72 hours after blast. We will continue to collect these samples at the rate that the mice are bred. We still need to complete IGFBP-3 KO blast only for 4 and 24 hours. We will also blast IGFBP-3 KO mice

and then treat within 4 and 24 hours with Compound 49b. We expect that we can complete these studies in year 2 of this grant.

The only real issue we have encountered in this work is the rate of IGFBP-3 KO mice breeding. They are slow to breed. This has delayed collection of retinal tissues after blast in the IGFBP-3 KO mice. However, we still should be able to complete Aim 2 within the 2nd year of the grant.

Key Research Accomplishments

- Demonstration that 26Psi blast induces increased TNF α , IL-1 β and increases apoptotic protein levels
- Demonstration that topical Compound 49b can inhibit the increased inflammatory and apoptotic protein levels if administered within 24 hours of blast

Reportable Outcomes

- Manuscript in J. of Neuroinflammation-- Compound 49b protects against blast-induced retinal injury
- Abstract on data in manuscript presented at Association for Research in Vision and Ophthalmology in Seattle, WA in May 2013
- Patent discussions ongoing with UT Research Foundation

Conclusions

In conclusion, exposure to ocular blast, similar to closed globe injuries observed in soldiers, increases key inflammatory and apoptotic proteins for up to 72 hours after blast exposure. This response occurred primarily in the cells of the ganglion cell layer of the retina. Compound 49b, a novel β -adrenergic receptor agonist, was able to mitigate the increased inflammatory and apoptotic markers, with optimal responses observed when treatment was initiated within at least 24 hours of blast exposure. Since Compound 49b has little observed toxicity and is an eye drop, it may offer a new therapy to protect the retina of soldiers after exposure to explosive devices in the combat field.

References

1. Sobaci G, Mutlu FM, Bayer A, Karagul S, and Yildirim E, Deadly weapon-related open-globe injuries: outcome assessment by the ocular trauma classification system. *American journal of ophthalmology*, 2000; 129: 47-53.
2. Weichel ED and Colyer MH, Combat ocular trauma and systemic injury. *Current opinion in ophthalmology*, 2008; 19: 519-25.
3. Kaur C, Singh J, Lim MK, et al., The response of neurons and microglia to blast injury in the rat brain. *Neuropathology and applied neurobiology*, 1995; 21: 369-77.
4. Koliatsos VE, Cernak I, Xu L, et al., A mouse model of blast injury to brain: initial pathological, neuropathological, and behavioral characterization. *Journal of neuropathology and experimental neurology*, 2011; 70: 399-416.
5. Cernak I, The importance of systemic response in the pathobiology of blast-induced neurotrauma. *Frontiers in neurology*, 2010; 1: 151.
6. Cockerham GC, Rice TA, Hewes EH, et al., Closed-eye ocular injuries in the Iraq and Afghanistan wars. *N Engl J Med*, 2011; 364: 2172-3.
7. Zhang Q, Guy K, Pagadala J, et al., Compound 49b Prevents Diabetes-Induced Apoptosis through Increased IGFBP-3 Levels. *Invest Ophthalmol Vis Sci*, 2012; 53: 3004-13.

Appendices

Compound 49b protects against blast-induced retinal injury

Youde Jiang¹, Li Liu¹, Jayaprakash Pagadala³, Duane D. Miller³, Jena J. Steinle^{1,2}

¹Department of Ophthalmology, ²Anatomy&Neurobiology, and ³Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163

Corresponding author: Jena J. Steinle, Associate Professor, Hamilton Eye Institute, Department of Ophthalmology, 930 Madison Ave, Suite 768A, Memphis, TN, 38163; Phone: (901) 448-1910; FAX: (901) 448-5028; email: jsteinl1@uthsc.edu

Running Title: Beta-adrenergic receptor agonist protects retina

Abstract

BACKGROUND: To determine whether Compound 49b, a novel beta-adrenergic receptor agonist, can prevent increased inflammatory and apoptotic markers in mice after exposure to ocular blast.

METHODS: Eyes from C57/BL6 mice were exposed to a blast of air from a paintball gun at 26psi. Eyes were collected 4 hours, 24 hours, and 72 hours after blast exposure. In a subset of mice, Compound 49b eye drops (1mM) were applied within 4 hours, 24 hours, or 72 hours of blast. Three days after exposure of blast, all mice were sacrificed. One eye was used for measurement of retinal proteins (TNF α , IL-1 β , Bax, Bcl-xL, caspase 3 and cytochrome C). The other eye was used for TUNEL labeling of apoptotic cells, which were co-labeled with NeuN to stain for retinal ganglion cells.

RESULTS: We found that ocular exposure to 26psi air pressure led to a significant increase in apoptotic and inflammatory mediators within 4 hours, which lasted throughout the time period investigated. When Compound 49b was initiated within 4 hours or 24 hours of blast injury, levels of apoptotic and inflammatory mediators was significantly reduced. Application of Compound 49b within 72 hours of blast injury reduced inflammatory mediators, but not to untreated levels.

CONCLUSIONS: Ocular blast injury produces a significant increase in key inflammatory and apoptotic markers in the retina as early as 4 hours after blast exposure. These inflammatory and apoptotic markers are significantly reduced if a beta-adrenergic receptor agonist is applied within 24 hours of blast exposure. Data suggest that local application of beta-adrenergic receptor agonists may be beneficial to reduce inflammatory and apoptotic markers.

Keywords: beta-adrenergic receptor agonists; apoptosis, cytokines

Background

Ocular trauma constitutes one of the most common causes of unilateral morbidity and blindness in the world today^[1]. During recent wars, many ocular injuries are caused by explosions with fragmentary munitions and are the 4th most common injury in Operation Iraqi Freedom^[2]. Due to improvements in body protective gear, the rates of combat-based morbidity and mortality have decreased, while the number of ocular injuries has increased (from 0.57% during the Civil War to 13% in Desert Storm)^[1, 8]. While all soldiers agree that eyewear is important, many are non-compliant because the eyewear becomes foggy, is bulky, or is unstylish^[2]. In addition to the compliance issue, the ability of eye protective gear is at present, limited. Even with improved eye protective wear, injuries still occur in 24% of blast injury cases. Thus, despite advances in military protective wear, the blast produced by many improvised explosive device (IEDs) is associated with closed, as well as open globe injuries, through the fragmentary munitions. Due to other life-threatening injuries that may occur after IED blast exposure, ocular repair and treatment is often delayed for as long as 3-4 days after the initial injury^[2, 8].

In order to better understand the damage to the eye after exposure to ocular blast, a good model needs to be developed. Unfortunately, prior to this year, little has existed. Whole body models of blast injury have been used to investigate the effects of blast on the major organ systems^[3] or blast injuries to the brain^[5]. These studies demonstrated that Kevlar protection is effective to protect internal organs from injury, but that the brain and eyes are still affected by the blast wave. Furthermore, work in the brain blast model demonstrated damage to the visual tracts of the brain; the retina itself was not fully examined in this study.^[4] To better mimic ocular trauma and allow for thorough characterization of retinal responses, a new model has been developed using an air blast from a paintball gun as the primary inducer of trauma^[9]. Using this model, Hines-Beard et al (2012) demonstrated that a pressure of 23-26psi produced a number of anterior with few posterior ocular injuries, using high-resolution optical coherence topography, gross pathology, and optokinetics^[9]. In this study of various blast pressures, the authors found only 1 eye after exposure to 26psi to have retinal, choroidal, or retinal pigmented epithelium (RPE) changes. This corresponds well with previous studies in Veterans^[6]. Despite the lack of gross pathology, it is probable that the posterior eye is still altered after exposure to blast, including increased levels of inflammatory or apoptotic markers. In order to investigate changes in retinal inflammatory and apoptotic mediators after blast, we employed the same model as described in^[9] and measured protein levels of key proteins within 4 hours, 1 day and 3 days after blast exposure.

Additionally, we have previously reported that β -adrenergic receptor agonists, particularly a novel drug, Compound 49b, have anti-apoptotic and anti-inflammatory properties in retinal endothelial cells and in a diabetic retinopathy model^[7, 10]. Compound 49b was based on the chemical structure of isoproterenol with chemical modifications to increase its ocular potency as a topical

treatment. Chemical properties of Compound 49b are in Table 1. The chemical structure of Compound 49b is patent pending (WO 2011112243 A2). Our hypothesis in this study was that topical application of Compound 49b within 24 hours of blast injury would prevent blast-induced increases in inflammatory mediators and apoptotic markers.

Methods

Mice. C57/BL6 mice were purchased from Charles River (Wilmington, MA) at 2 months of age. Mice were exposure to an ocular blast of 26psi to both eyes using an air blast from a paintball gun^[9]. Pressures were measured before and after exposure of each eye to a blast. The pressures were measured and analyzed using Labview software (National Instruments, Austin, TX).

Both eyes of the mice were exposed to the ocular blast. In one subset of mice, eyes were collected at 4 hours post-blast, 24 hours post-blast, 72-hours post blast or at 72 hours without exposure to the blast. In the second subset of mice, both eyes were blasted; however, a novel β -adrenergic receptor agonist, Compound 49b (1mM), was applied topically within 4 hours, 24 hours or 72 hours post-blast. For the Compound 49b-treated mice, mice received daily Compound 49b treatment for up to 3 days. For example, for the 4 hour treatment group, the mice received the first treatment within 4 hours post-blast, then another treatment 24 hours, 48 hours, and 72 hours post-blast (for a total of 4 treatments), while 72 hour post-blast mice only received 1 treatment of Compound 49b prior to sacrifice. All mice were sacrificed 3 days post-blast for the Compound 49b treated mice. Ten mice were used at each time point for all experiments.

Western Blotting. At the appropriate time after blast or Compound 49b treatments, one eye was used for protein analyses. For Western blot analyses, retinal lysates were collected into lysis buffer containing the protease and phosphatase inhibitors and scraped into the tubes. Retinal extracts were prepared by sonication. Equal amounts of protein from the cell or tissue extracts were separated on the pre-cast tris-glycine gel (Invitrogen, Carlsbad, CA), blotted onto a nitrocellulose membrane. After blocking in TBST (10mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 0.1% Tween 20) and 5% (w/v) BSA, the membrane was treated with appropriate primary antibodies followed by incubation with secondary antibodies labeled with horseradish peroxidase. Antigen-antibody complexes were detected by chemilluminescence reagent kit (Thermo Scientific). Primary antibodies used were Cytochrome C, Bax, and Bcl-xL, NFkB, and phosphorylated NFkB (all purchased from Cell Signaling, Danvers, MA).

ELISA Analysis. A cleaved caspase 3 ELISA (Cell Signaling, Danvers, MA) was used to measure levels of the active apoptotic marker in whole retinal lysates. TNF α and IL-1 β protein concentrations were measured using a TNF α and IL-1 β ELISA, respectively

(ThermoFisher, Pittsburgh, PA). All ELISAs were done according to manufacturer's instructions with equal protein loaded into all wells.

Terminal deoxynucleotidyl transferase mediated dUTP Nick End Labeling assay (TUNEL). TUNEL was done on 10um cryosections of mouse retina according to manufacturer's instructions using the ApopTag-FITC kit (Millipore, Bilerica, MA) to localize apoptotic cells in the retina at the various time points. Co-localization of TUNEL positive cells with NeuN antibody (Abcam) was done to demonstrate which cell types were undergoing apoptosis.

Statistics. For all analyses, all experiments were done in triplicate. Data is presented as mean \pm SEM, with statistical analyses using Kruskal-Wallis non-parametric testing, followed by Dunn's test.

Results.

Blast exposure increases TNF α and IL-1 β levels in retinal lysates as early as 4 hours, which is mitigated by topical Compound 49b. Since a thorough analyses of inflammatory and apoptotic markers after blast exposure has not been reported, we chose to investigate levels of TNF α and IL-1 β , both key proteins in other retinal diseases^[11, 12], within 4 hours, 24 hours and 72 hours of exposure to 26psi blast. We found that protein levels of both TNF α and IL-1 β are significantly increased within 4 hours of blast exposure and remain elevated for the 72 hours investigated (Figure 1). Additionally, we found that if topical Compound 49b (1mM) was applied within 4, 24 or 72 hours of blast exposure, the β -adrenergic receptor agonist was able to significantly reduce levels of both TNF α and IL-1 β (Figure 1). In the case of TNF α , treatments within 4 or 24 hours of blast exposure were able to return TNF α levels to a level not significantly different than an eye not exposed to blast at all.

Compound 49b reduces apoptotic proteins after exposure to ocular blast. Because activation of inflammatory mediators often leads to apoptosis^[13, 14], we evaluated key apoptotic proteins (Bax, Cytochrome C, cleaved caspase 3) and an anti-apoptotic marker (BcL-xL) after exposure to blast alone or blast+Compound 49b at 4, 24, and 72 hours post-blast. Blast significantly increased pro-apoptotic markers and reduced BcL-xL. Compound 49b effectively reduced Bax and Cytochrome C and increased BcL-xL if applied within 24 hours of blast. Compound 49b was effective in reducing cleaved caspase 3 at all time points investigated. Taken together, blast induces a strong apoptotic response, which is mitigated by application of Compound 49b, best applied within 1 day of blast exposure.

Ocular blast induces apoptosis of cells in ganglion cell layer. In order to visualize which cells were undergoing apoptosis after ocular

blast exposure, we performed TUNEL labeling of retina sections with co-localization with NeuN to label retinal ganglion cells after blast or blast+Compound 49b. It is clear that apoptosis is occurring in cells of the ganglion cell layer as early as 4 hours after blast, becoming more pronounced over the 72 hours of analyses. Compound 49b reduces this apoptosis, which is in agreement with the apoptotic protein marker analyses.

Discussion.

Ocular trauma is a leading cause of vision loss for soldiers, as well as the general public ^[8, 15]. Unfortunately, little is known of the effects of exposure of blast pressure to the retina. Using the same model as used for this work, Hines-Beard only observed changes to the RPE in 1 eye ^[9]. While the morphology of the retina may not have changed, the proteins within the retina likely have become activated and initiated changes to be manifested in the morphology in the future. We found that within 4 hours of exposure to ocular blast, a significant increase in key inflammatory and apoptotic markers could be observed. This was associated with increased TUNEL labeling within the cells of the ganglion cell layer, which became more pronounced with additional exposure time of inflammatory and apoptotic markers.

Little is known on the cellular changes following exposure to ocular blast or in closed-globe ocular injuries. For most ocular trauma studies, work has focused on corneal burns or trauma. However, since it is likely that other ocular targets are affected following exposure to the blast, literature on cellular changes in these targets may be relevant. Mice receiving a chemical burn to the cornea had significantly increased levels of TNF α and IL-1 β , as well as macrophage migration inhibitory factor ^[16]. In a review of animal models of retinal injury, retinal ganglion cell apoptosis and inflammation are key points of discussion ^[17]. While the majority of the discussion in the work by Blanch ^[17] was focused on axotomy of retinal ganglion cells or the optic nerve, the findings are similar to our observations after exposure to ocular blast, with increased levels of inflammatory mediators and apoptotic rates. In a subsequent paper on retinal changes in a closed globe injury model, authors describe increased TUNEL labeling and apoptosis of photoreceptors in the retina, after injury was induced by firing an air gun pellet or ball bearing into the mouse eye ^[18]. In this model involving projectiles into the eye, photoreceptor apoptosis and necrosis were observed, but specific apoptotic proteins or inflammatory proteins were not investigated. It is clear that further work on the cellular changes in the retina after injury is warranted.

Our findings of increased inflammatory and apoptotic markers after exposure to ocular blast agree with work from corneal burns or other closed globe models. A recent report from British soldiers in Iraq and Afghanistan investigated ocular injuries, with the primary injury being trauma from exposure to a foreign body. In that work, the authors concluded that treatments could be safely delayed for 24 hours to allow for treatment of more life-threatening injuries ^[19]. Our results with Compound 49b eye drop therapy support this conclusion, demonstrating that Compound 49b can reduce both inflammatory mediators and apoptotic markers for up to 72 hours after exposure to blast. We have previously reported that Compound 49b is effective in reducing TNF α and apoptotic

proteins in diabetic animals up to 6 months, when applied daily ^[7]. Isoproterenol was equally effective at reducing TNF α and apoptosis, but it had unwanted cardiovascular effects ^[10]. Future work will focus on the mechanisms by which Compound 49b can reduce inflammatory and apoptotic markers induced by ocular blast exposure.

In conclusion, exposure to ocular blast, similar to closed globe injuries observed in soldiers, increases key inflammatory and apoptotic proteins for up to 72 hours after blast exposure. This response occurred primarily in the cells of the ganglion cell layer of the retina. Compound 49b, a novel β -adrenergic receptor agonist, was able to mitigate the increased inflammatory and apoptotic markers, with optimal responses observed when treatment was initiated within at least 24 hours of blast exposure. Since Compound 49b has little observed toxicity and is an eye drop, it may offer a new therapy to protect the retina of soldiers after exposure to explosive devices in the combat field.

Abbreviations

TNF α : tumor necrosis factor alpha; IL-1 β :interleukin-1beta; TUNEL:Terminal deoxynucleotidyl transferase mediated dUTP Nick End Labeling

Competing Interests

YJ, DM, and JS are inventors of Compound 49b for blast injury

Author Contributions

YJ completed all experiments and analyzed the data. LL completed the immunohistochemical staining. DM and JP designed Compound 49b. JS designed the experiments, assisted with data analyses, and wrote the paper. All authors have read and approved the final version of the manuscript.

Acknowledgements. We appreciate advice on the blast model from Dr. Tonia Rex. This work is supported by a grant from U.S. Army Medical Research and Material Command (W81XWH-12-1-0318), NIH R01 (EY022045 to JJS), JDRF Priority Research Grant (2-2011-597 to JJS); Oxnard Foundation (JJS); Research to Prevent Blindness Award (PI:Barrett Haik); and NEI Vision Core Grant: PHS 3P30 EY013080 (PI: Dianna Johnson).

Department of Defense Non-endorsement disclaimer: The views, opinions, and/or findings contained in this research presentation are those of the authors and do not necessarily reflect the views of the Department of Defense and should not be construed as an official DoD/Army position, policy, or decision unless so designated by other documentation. No official endorsement should be made.

References

1. Sobaci G, Mutlu FM, Bayer A, Karagul S, and Yildirim E, Deadly weapon-related open-globe injuries: outcome assessment by the ocular trauma classification system. *American journal of ophthalmology*, 2000; 129: 47-53.
2. Weichel ED and Colyer MH, Combat ocular trauma and systemic injury. *Current opinion in ophthalmology*, 2008; 19: 519-25.
3. Kaur C, Singh J, Lim MK, et al., The response of neurons and microglia to blast injury in the rat brain. *Neuropathology and applied neurobiology*, 1995; 21: 369-77.
4. Koliatsos VE, Cernak I, Xu L, et al., A mouse model of blast injury to brain: initial pathological, neuropathological, and behavioral characterization. *Journal of neuropathology and experimental neurology*, 2011; 70: 399-416.
5. Cernak I, The importance of systemic response in the pathobiology of blast-induced neurotrauma. *Frontiers in neurology*, 2010; 1: 151.
6. Cockerham GC, Rice TA, Hewes EH, et al., Closed-eye ocular injuries in the Iraq and Afghanistan wars. *N Engl J Med*, 2011; 364: 2172-3.
7. Zhang Q, Guy K, Pagadala J, et al., Compound 49b Prevents Diabetes-Induced Apoptosis through Increased IGFBP-3 Levels. *Invest Ophthalmol Vis Sci*, 2012; 53: 3004-13.
8. Weichel ED, Colyer MH, Ludlow SE, Bower KS, and Eiseman AS, Combat ocular trauma visual outcomes during operations iraqi and enduring freedom. *Ophthalmology*, 2008; 115: 2235-45.
9. Hines-Beard J, Marchetta J, Gordon S, et al., A mouse model of ocular blast injury that induces closed globe anterior and posterior pole damage. *Exp Eye Res*, 2012; 99: 63-70.
10. Jiang Y, Walker RJ, Kern TS, and Steinle JJ, Application of isoproterenol inhibits diabetic-like changes in the rat retina. *Exp Eye Res*, 2010; 91: 171-9.
11. Jousen AM, Doehmen S, Le ML, et al., TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. *Mol Vis*, 2009; 15: 1418-28.
12. Vincent JA and Mohr S, Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. *Diabetes*, 2007; 56: 224-30.
13. Li L, Wu W, Huang W, et al., NF-kappaB RNAi decreases the Bax/Bcl-2 ratio and inhibits TNF-alpha-induced apoptosis in human alveolar epithelial cells. *Inflamm Res*, 2013.
14. Busik JV, Mohr S, and Grant MB, Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. *Diabetes*, 2008; 57: 1952-65.
15. Cockerham GC, Goodrich GL, Weichel ED, et al., Eye and visual function in traumatic brain injury. *Journal of rehabilitation research and development*, 2009; 46: 811-8.
16. Oh SY, Choi JS, Kim EJ, Chuck RS, and Park CY, The role of macrophage migration inhibitory factor in ocular surface disease pathogenesis after chemical burn in the murine eye. *Mol Vis*, 2010; 16: 2402-11.
17. Blanch RJ, Ahmed Z, Berry M, Scott RA, and Logan A, Animal models of retinal injury. *Invest Ophthalmol Vis Sci*, 2012; 53: 2913-20.
18. Blanch RJ, Ahmed Z, Sik A, et al., Neuroretinal cell death in a murine model of closed globe injury: pathological and functional characterization. *Invest Ophthalmol Vis Sci*, 2012; 53: 7220-6.
19. Blanch RJ, Bindra MS, Jacks AS, and Scott RA, Ophthalmic injuries in British Armed Forces in Iraq and Afghanistan. *Eye (Lond)*, 2011; 25: 218-23.

Table 1

Compound 49b:

Molecular Formula (in salt)	C ₁₉ H ₂₆ ClNO ₆
Molecular Weight (in salt)	399.87
Molecular Formula (in Neutral)	C ₁₉ H ₂₅ NO ₆
Molecular Weight (in Neutral)	363.40
Log P	1.92
pKa	~ 9

Molecular weight and Chemical Formula of the Compound 49b in salt form is 399.87 and C₁₉H₂₆ClNO₆. In Neutral form Molecular Weight: 363.40; Chemical Formula: C₁₉H₂₅NO₆.

Compound 49b pKa is around 9. We also have measured the octanol-water partition coefficient (*Log P*) of compound 49b (1.92) as measure of their lipophilicity. *Log P* was calculated using ChemDraw Ultra version 8.0 (CambridgeSoft Corporation, Cambridge, MA).

Figure Legends.

Figure 1. ELISA results for TNF α (left) and IL-1 β (right) in mouse retina without exposure to blast (NT) or exposure to blast for 4, 24, or 72 hours or exposure to blast+Compound 49b for 4, 24, or 72 hours. *P<0.05 vs. NT. #P<0.05 vs. blast only at the same time point. N=5 mice for each group.

Figure 2. Western blot results for key pro-apoptotic proteins (Cytochrome C and Bax—top) and anti-apoptotic protein Bcl-xL (bottom left). ELISA results for cleaved caspase 3. *P<0.05 vs. NT. #P<0.05 vs. blast only at the same time point. N=5 mice for each group.

Figure 3. TUNEL labeling and NeuN (retinal ganglion cell marker) in untreated mice (A), 4 hours post blast (B), 4 hours post-blast+49b (C), 24 hours post-blast (D), 24 hours post-blast+49b (E), 72 hours post-blast (F) and 72 hours post-blast+49b (G). TUNEL labeling is green with NeuN staining is red. Scale bar is 50 μ m.

Figure 1




Figure 2




Figure 3

